UNIVERSITY OF SOUTHERN CALIFORNIA
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1880-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://startusc.com
Clinical Trials
743
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (618 trials with phase data)• Click on a phase to view related trials
eMOTION: Examining Implicit Attitudes in Physical Activity Engagement
- Conditions
- Physical ActivityOverweight or ObesityCancer
- First Posted Date
- 2025-07-01
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 120
- Registration Number
- NCT07044570
- Locations
- 🇺🇸
Univeristy of Southern California, Los Angeles, California, United States
Feasibility and Safety of the Airway Exchange Broncholaryngoscope (AEBLScope)
- Conditions
- Tracheotomy PatientsAirway ManagementAirway Disease
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 10
- Registration Number
- NCT07033702
- Locations
- 🇺🇸
Keck Hospital of USC, Los Angeles, California, United States
🇺🇸Los Angeles General Medical Center, Los Angeles, California, United States
Treatment Decision-Making Among Patients With Chronic Rhinosinusitis
- Conditions
- Chronic Rhinosinusitis (CRS)
- First Posted Date
- 2025-06-08
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 50
- Registration Number
- NCT07010679
Tirzepatide for Alcohol Use Disorder
- Conditions
- Alcohol Use DisorderObesity and Overweight
- Interventions
- Drug: Placebo injections
- First Posted Date
- 2025-05-29
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 42
- Registration Number
- NCT06994338
- Locations
- 🇺🇸
Keck School of Medicine, University of Southern California, Los Angeles, California, United States
Alzheimer's Tau Platform: Master Protocol
- Conditions
- Preclinical Alzheimer&Amp;#39;s DiseaseAlzheimer DiseaseProdromal Alzheimer's Disease
- Interventions
- Drug: Tau1Drug: Tau2
- First Posted Date
- 2025-05-04
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 750
- Registration Number
- NCT06957418
- Prev
- 1
- 2
- 3
- 4
- 5
- 149
- Next
News
NeOnc Technologies Secures $50 Million Investment to Expand Brain Cancer Clinical Trials in MENA Region
NeOnc Technologies signed a non-binding term sheet with Quazar Investment for a $50 million equity investment to establish a UAE-based clinical platform focused on the Middle East and North Africa region.
Mendaera's Focalist Handheld Robotic System Receives FDA Clearance for Ultrasound-Guided Procedures
Mendaera received FDA 510(k) clearance for its Focalist handheld robotic system designed to enhance precision in ultrasound-guided needle placement procedures.
Maternal Cardiometabolic Risk Factors During Pregnancy Linked to Higher Blood Pressure in Children
A recent study published in JAMA Network Open reveals that maternal obesity, gestational diabetes, and hypertensive disorders during pregnancy are associated with elevated blood pressure in offspring.
NeOnc Technologies to List on Nasdaq Global Market with Novel Blood-Brain Barrier Therapeutics
NeOnc Technologies Holdings, Inc. will begin trading on the Nasdaq Global Market under the ticker symbol "NTHI" on March 26, 2025, following SEC approval of its registration statement.
American Cancer Society Unveils Strategic Vision: $517M Research Initiative Focuses on Early Detection and Diversity
The American Cancer Society (ACS) has committed $517 million to research grants, with a significant focus on supporting early-career investigators and promoting diversity in cancer research.
USC Secures $10.8M PCORI Grant to Compare Hip Fracture Surgery Approaches in Elderly Patients
USC researchers have received a $10.8 million PCORI grant to conduct the FASTER-Hip trial, comparing hip replacement versus internal fixation for minimally displaced femoral neck fractures in older adults.